236 related articles for article (PubMed ID: 27208382)
41. Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.
Mano Y; Usui T; Kamimura H
Eur J Drug Metab Pharmacokinet; 2006; 31(2):117-21. PubMed ID: 16898080
[TBL] [Abstract][Full Text] [Related]
42. Lack of biliary excretion of Cd linked to an inherent defect of the canalicular isoform of multidrug resistance protein (cMrp) does not abnormally stimulate accumulation of Cd in the Eisai hyperbilirubinemic (EHB) rat liver.
Sugawara N; Lai YR; Arizono K; Kitajima T; Inoue H
Arch Toxicol; 1997; 71(5):336-9. PubMed ID: 9137813
[TBL] [Abstract][Full Text] [Related]
43. Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer.
Yamada T; Arai T; Nagino M; Oda K; Shoda J; Suzuki H; Sugiyama Y; Nimura Y
Langenbecks Arch Surg; 2005 Sep; 390(5):421-9. PubMed ID: 15965653
[TBL] [Abstract][Full Text] [Related]
44. A strategy to reduce biliary clearance in early drug discovery.
Rioux N; Bellavance E; Poirier H; Dupuis M; Garneau M; Ribadeneira MD; Duan J
J Pharmacol Toxicol Methods; 2013; 68(3):346-8. PubMed ID: 23518065
[TBL] [Abstract][Full Text] [Related]
45. Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR ) Wistar rats.
Leslie EM; Ghibellini G; Nezasa K; Brouwer KL
Carcinogenesis; 2007 Dec; 28(12):2650-6. PubMed ID: 17724374
[TBL] [Abstract][Full Text] [Related]
46. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
[TBL] [Abstract][Full Text] [Related]
47. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
48. Carbon monoxide stimulates mrp2-dependent excretion of bilirubin-IXalpha into bile in the perfused rat liver.
Norimizu S; Kudo A; Kajimura M; Ishikawa K; Taniai H; Yamaguchi T; Fujii K; Arii S; Nimura Y; Suematsu M
Antioxid Redox Signal; 2003 Aug; 5(4):449-56. PubMed ID: 13678533
[TBL] [Abstract][Full Text] [Related]
49. Effects of organic anions and bile acid conjugates on biliary excretion of pravastatin in the rat.
Fukumura S; Takikawa H; Yamanaka M
Pharm Res; 1998 Jan; 15(1):72-6. PubMed ID: 9487549
[TBL] [Abstract][Full Text] [Related]
50. Intestinal ischemia-reperfusion suppresses biliary excretion of hepatic organic anion transporting polypeptides substrate.
Maruyama H; Ogura J; Fujikawa A; Terada Y; Tsujimoto T; Koizumi T; Kuwayama K; Kobayashi M; Yamaguchi H; Iseki K
J Pharm Pharm Sci; 2013; 16(5):722-31. PubMed ID: 24393554
[TBL] [Abstract][Full Text] [Related]
51. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2).
Chu XY; Strauss JR; Mariano MA; Li J; Newton DJ; Cai X; Wang RW; Yabut J; Hartley DP; Evans DC; Evers R
J Pharmacol Exp Ther; 2006 May; 317(2):579-89. PubMed ID: 16421286
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide.
Yamada T; Niinuma K; Lemaire M; Terasaki T; Sugiyama Y
J Pharmacol Exp Ther; 1996 Dec; 279(3):1357-64. PubMed ID: 8968360
[TBL] [Abstract][Full Text] [Related]
53. Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration.
Hu Y; Sampson KE; Heyde BR; Mandrell KM; Li N; Zutshi A; Lai Y
Drug Metab Dispos; 2009 Apr; 37(4):841-6. PubMed ID: 19139164
[TBL] [Abstract][Full Text] [Related]
54. Effect of OATP-binding on the prediction of biliary excretion.
Sharifi M; Ghafourian T
Xenobiotica; 2017 Jul; 47(7):614-631. PubMed ID: 27485154
[TBL] [Abstract][Full Text] [Related]
55. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.
Matsushima S; Maeda K; Hayashi H; Debori Y; Schinkel AH; Schuetz JD; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2008 May; 73(5):1474-83. PubMed ID: 18245269
[TBL] [Abstract][Full Text] [Related]
56. Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
Kwon MH; Yoon JN; Baek YJ; Kim YC; Cho YY; Kang HE
Biopharm Drug Dispos; 2016 Sep; 37(6):352-65. PubMed ID: 27241939
[TBL] [Abstract][Full Text] [Related]
57. Key determinants of the circulatory exposure of organic anions: differences in hepatic uptake between multidrug resistance-associated protein 2 (Mrp2)-deficient rats and wild-type rats.
Kosaka K; Watanabe T; Susukida T; Aoki S; Sekine S; Kume T; Ito K
Xenobiotica; 2015; 45(6):556-62. PubMed ID: 25539456
[TBL] [Abstract][Full Text] [Related]
58. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
59. In silico prediction of biliary excretion of drugs in rats based on physicochemical properties.
Luo G; Johnson S; Hsueh MM; Zheng J; Cai H; Xin B; Chong S; He K; Harper TW
Drug Metab Dispos; 2010 Mar; 38(3):422-30. PubMed ID: 19995888
[TBL] [Abstract][Full Text] [Related]
60. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.
Asakura E; Nakayama H; Sugie M; Zhao YL; Nadai M; Kitaichi K; Shimizu A; Miyoshi M; Takagi K; Takagi K; Hasegawa T
Eur J Pharmacol; 2004 Jan; 484(2-3):333-9. PubMed ID: 14744620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
